Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 1 17Phase 1/2 10Phase 3 7Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Glioma 2Thyroid Neoplasms 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Melanoma 1Lung Neoplasms 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Nivolumab 5aldesleukin 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Immune Checkpoint Inhibitors 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1pembrolizumab 1pasireotide 1encorafenib 1dabrafenib 1binimetinib 1Vindesine 1Standard of Care 1Specimen Handling 1Sevoflurane 1Propofol 1Pharmaceutical Preparations 1Patient-Specific Modeling 1Isoflurane 1Interleukins 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fibrin Tissue Adhesive 1Etanercept 1Desflurane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Melanoma × dabrafenib × Clear all
NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡